Skip to Content

Press Releases

Wittman, Krishnamoorthi, Colleagues Urge Administration to Prohibit Illicit Vaping Products from China

Today, Congressman Rob Wittman (R-VA) and Congressman Raja Krishnamoorthi (D-IL) sent a bipartisan letter to administration officials, urging the Food and Drug Administration (FDA) and U.S. Department of Justice (DOJ) to address the proliferation of illicit vaping products from the People’s Republic of China (PRC) in the United States.

“We cannot allow the Chinese Communist Party to infiltrate the U.S. market with illicit vaping products, circumventing the FDA,” said Rep. Wittman. “With approximately 90 percent of vaping products illegally entering the United States coming from China, it is more urgent than ever that the federal government take action to halt the importation of these illicit products from one of our foremost adversaries.”

“As the youth vaping epidemic continues to harm millions of American children, we must use every tool at our disposal to crack down on illicit vaping products, including halting their illegal importation from the People’s Republic of China,”said Rep. Krishnamoorthi. “At a time when the vast majority of illegal vaping imports come from the PRC, especially those specifically designed to appeal to children, it is imperative that federal agencies work together to prevent these illicit products from reaching our kids.”

Both congressmen sit on the House Select on Committee on the Chinese Communist Party, where they work on a bipartisan basis to build consensus on the threat posed by the Chinese Communist Party and develop a plan of action to defend the American people, our economy, and our values.

The letter was also signed by Reps. Andy Barr (R-KY), André Carson (D-IN), Neal Dunn (R-FL), Mike Gallagher (R-WI), Ashley Hinson (R-IA), Dusty Johnson (R-SD), Darin LaHood (R-IL), Blaine Luetkemeyer (R-MO), Mikie Sherrill (D-NJ), and Ritchie Torres (D-NY).

To read the full letter, click here or scroll below.

___

Robert Califf, M.D.
Commissioner
Food and Drug Administration
5630 Fishers Lane
Rockville, MD 20852

Brian Boynton
Consumer Protection Branch
U.S. Department of Justice
Civil Division
950 Pennsylvania Ave, NW
Washington, DC 20530

Dear Doctor Califf and Principal Deputy Assistant Attorney General Boynton: 

            We are writing to draw your attention to the extreme proliferation of illicit vaping products from the People’s Republic of China (PRC). Once imported illegally from the PRC, these unregulated products can be easily bought online and in brick-and-mortar stores across the United States. We ask you to work with the Customs and Border Protection (CBP) agency to address this urgent problem with all due speed.

            The 2009 Tobacco Control Act (TCA) strictly prohibits manufacturers from introducing new products in the U.S. without going through the Pre-Market Authorization process. However, an estimated 90 percent of illicit vaping products without pre-market authorization arrive in the United States from manufacturers in the PRC, where flavored vaping products have been banned since 2022 for the Chinese domestic market. The vaping products often have custom designs, kid-friendly flavors, and can be quickly delivered to the United States. According to one news source, vaping products have been able to avoid detection and seizure at the border by changing a banned product’s name to a similar sounding one, while using the same QR code as the one used in the banned product, and the same licensing code assigned to the manufacturer by the Chinese tobacco authorities.

            These vaping products from the PRC are now more than half of all vaping products sold in the U.S. and are contributing significantly to underage vaping rates. According to data from the CDC Foundation, flavored vape sales have surged 64 percent over the past three and half years, to 18.4 million vaping products per month in September 2023.  By September 2023, disposable vapes made up 57.2 percent of  e-cigarette sales in retail-tracked channels (which does not include online or vape shops). According to an article in the New York Times, there were more than 5,800 disposable vaping products being sold in kid-friendly flavors as of June 2023, which is a 1,500 percent increase from 2020.

            Deeply concerning to us, in 2023, 10 percent of high schoolers and 4.6 percent of middle schoolers, or 2.1 million youth, used e-cigarettes. While we were encouraged to see that FDA in May 2023 issued an import alert for disposable Elf Bar e-cigarettes, which are now the most popular e-cigarettes with youth, recent news reports suggest that Elf Bar is successfully evading this import ban.

            FDA is now more than two years past a court-ordered deadline to complete its review of timely-filed pre-market tobacco product applications (“PMTA”) from e-cigarette manufacturers. In its most recent filing with the court, FDA has indicated that it may not meet its most recent estimate to complete its review of large market share products by the end of this year. It is imperative that FDA complete these reviews without further delay.

            Further, we are especially concerned with the finding that recent unlawful vaping imports are dominated by high-volume products containing approximately as much nicotine as in several cartons of cigarettes. Many brands promise users thousands of puffs in a single device, delivering more cumulative quantities of nicotine than traditional cigarettes. According to one news report, one brightly colored, fruit-flavored vaping product from the PRC, designed as a highlighter for youth to easily conceal, delivered as much as 50 milligrams of nicotine, or the equivalent of 50 cigarettes, in a single device.

            These recent developments threaten to derail the gains made in helping young people stay free from nicotine addiction and carry serious public health implications for decades to come. To address these serious concerns, we respectfully ask you to address the following questions: 

  1. Is FDA on track for completing its review of all large market share PMTAs by December 2023? 
  2. What is FDA’s position on a comprehensive approach to combat the proliferation of illicit vapes, including those from the PRC, including reforms outlined in the bipartisan letter from 33 Attorneys General?
  3. Does the FDA or the DOJ have plans to initiate further civil or criminal proceedings against egregious violations by manufacturers, wherever located, including injunctions, civil monetary penalties, and criminal prosecution?  
  4. What steps is FDA taking to more aggressively prevent the importation of illegal vapor products? Specifically: 
      1. Does the FDA plan to issue additional import alerts to address all known illegal products and their manufacturers?
      2. Has the FDA provided CBP a complete list of vapor products that (a) have received a Marketing Granted Order, and (b) have PMTAs pending since September 9, 2020? 
  1. How many vapor or vapor-related cases have been referred to DOJ from FDA in the preceding 12-month period?  How many, if any, referrals are currently pending with DOJ?  
  2. Has DOJ provided FDA with guidance regarding the type(s) of vapor cases that are appropriate for referral to DOJ?  
  3. What is DOJ’s internal review process or procedure once a referral has been received from FDA?  
  4. Does DOJ have sufficient resources or expertise to litigate vapor-related referrals from FDA? 

###